1. Home
  2. CMCL vs CHRS Comparison

CMCL vs CHRS Comparison

Compare CMCL & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Caledonia Mining Corporation Plc

CMCL

Caledonia Mining Corporation Plc

HOLD

Current Price

$19.38

Market Cap

396.3M

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.46

Market Cap

209.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMCL
CHRS
Founded
1992
2010
Country
Jersey
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
396.3M
209.8M
IPO Year
2003
2014

Fundamental Metrics

Financial Performance
Metric
CMCL
CHRS
Price
$19.38
$1.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$28.00
$5.51
AVG Volume (30 Days)
243.8K
950.1K
Earning Date
05-11-2026
05-07-2026
Dividend Yield
2.48%
N/A
EPS Growth
N/A
472.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$38.54
$73.08
Revenue Next Year
N/A
$30.94
P/E Ratio
$10.88
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.45
$0.73
52 Week High
$38.75
$2.62

Technical Indicators

Market Signals
Indicator
CMCL
CHRS
Relative Strength Index (RSI) 39.44 46.49
Support Level $18.45 $1.37
Resistance Level $21.80 $1.79
Average True Range (ATR) 0.80 0.08
MACD 0.01 0.01
Stochastic Oscillator 23.74 53.19

Price Performance

Historical Comparison
CMCL
CHRS

About CMCL Caledonia Mining Corporation Plc

Caledonia Mining Corp PLC is a gold exploration, development, and mining company. The company's segment includes Blanket, South Africa, Bilboes Oxide mine, and E&E projects. The company generates the majority of its revenue from the Blanket project. The Blanket Mine is located in the south-west of Zimbabwe and operates at a depth of approximately 750 meters below the surface. Its project includes Maligreen and Motapa.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: